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Introduction {#sec1}
============

Dendritic cells (DCs) constitute the major group of antigen-presenting cells that constantly patrol the body for microbes and are essential for linking innate and adaptive immune responses ([@bib4]). DCs are equipped with a diverse membrane receptor repertoire to take up pathogens including Toll-like receptors, scavenger receptors, and C-type lectins, such as the mannose receptor and the dendritic cell-specific intercellular adhesion molecule grabbing non-integrin receptor (DC-SIGN) ([@bib3], [@bib50], [@bib8], [@bib25], [@bib23]). Engagement of these receptors with their ligand is accompanied by cytoskeletal changes, which allow for the capture and engulfment of phagocytic targets ([@bib49], [@bib5]). Actin polymerization is instrumental in forming a nascent phagosome for pathogen engulfment, and actin-driven mechanical forces enable pathogen internalization ([@bib43]). In addition, phagocytosis is dependent on plasma membrane organization and loss of membrane structure results in impaired pathogen recognition, defective migration, and compromised immunological synapse formation ([@bib1], [@bib27], [@bib8]). Galectins, a family of ß-galactoside-binding proteins, have been recently identified as a novel mechanism of membrane organization ([@bib35], [@bib21], [@bib44]) due to their ability to interact with and cross-link specific carbohydrate structures. As such, Galectins can simultaneously interact with multiple glycoconjugates, thereby regulating the dynamics of glycosylated-binding partners, limiting receptor internalization, and establishing membrane microdomains ([@bib21]). Notably, Galectins are also abundantly expressed intracellularly, although their cytosolic functions are not well characterized ([@bib29], [@bib32], [@bib39], [@bib40]). Recently, Galectins have been discovered as novel regulators of several immune processes, such as T cell homeostasis, inflammation, and immune disorders ([@bib54], [@bib58], [@bib19], [@bib48]).

Galectin-9 was first discovered as an eosinophil chemoattractant, and to date, most studies have focused on studying Galectin-9 in inflammation or infection processes ([@bib34], [@bib15], [@bib30]). Extracellular Galectin-9 has been implicated in inhibiting T cell immunity by promoting T cell apoptosis and differentiation into regulatory T cells ([@bib2], [@bib7], [@bib64]). Furthermore, extracellular Galectin-9 acts as a suppressor of B cell signaling by binding to the B cell receptor ([@bib12], [@bib24]). Although these studies indicate that Galectin-9 plays an inhibitory role on lymphocytes, its function in myeloid cells remains poorly understood. Moreover, Galectin-9 is also highly expressed intracellularly, and although implicated in protein-protein interactions and mRNA splicing ([@bib39], [@bib54], [@bib26]), the function of cytosolic Galectin-9 in the immune system continues to be ill defined.

Here, we demonstrate that intracellular Galectin-9 is essential for sustaining cortical actin cytoskeleton rigidity and phagocytosis in DCs. Our work indicates a novel evolutionary conserved mechanism by which intracellular Galectins stabilize plasma membrane structure by actin cytoskeleton reorganization.

Results {#sec2}
=======

Galectins Are Essential in Governing Human Dendritic Cell Function {#sec2.1}
------------------------------------------------------------------

The role of Galectins in the initiation of the immune response is poorly understood, and although Galectin-3 has been implicated in macrophage-mediated uptake in mice ([@bib49]), few studies have been performed to elucidate Galectin function in DCs ([@bib17], [@bib37], [@bib30], [@bib16]). To address this question, we generated DCs lacking Galectin-3 and/or Galectin-9 by electroporating human monocyte-derived dendritic cells (moDCs) with either a specific *galectin* small interfering RNA (siRNA) (*gal3* and/or *gal9*) or a non-targeting (NT) siRNA control before challenge them with fluorescein isothiocyanate (FITC)-labeled zymosan particles, a fungal cell wall extract ([@bib18]). Subsequent immunolabeling without permeabilization using an antibody directed against FITC allowed for selective labeling of membrane-bound particles. Galectin-9 and Galectin-3 protein knockdowns were confirmed by flow cytometry showing that both proteins were depleted to a similar extent (70%, [Figures 1](#fig1){ref-type="fig"}A and 1B). The efficiency of Galectin knockdown was comparable between cells transfected with a single siRNA or with dual siRNA, and Galectin-9 knockdown (Gal-9 KD) did not affect Galectin-3 expression, or vice versa ([Figure S1](#mmc1){ref-type="supplementary-material"}). Depletion of Galectin-9 impaired particle uptake to a greater extent when compared with that observed upon Galectin-3 knockdown ([Figures 1](#fig1){ref-type="fig"}C, 1D, and 1E). Moreover, there was no additive effect of knocking down both Galectin-9 and Galectin-3 ([Figure 1](#fig1){ref-type="fig"}E). Taken together, these data demonstrate that Galectins are required for phagocytosis by DCs, and indicates that Galectin-9 is a major player in this process.Figure 1Galectin-9 Is Required for Dendritic Cell Function(A and B) moDCs were transfected with *gal9* siRNA and/or *gal3* siRNA or a non-targeting siRNA (NT). Surface only (A) and total (B) Galectin-9 and Galectin-3 knockdown were confirmed by flow cytometry 48 h after transfection. Red population, NT siRNA; blue population, *gal9* and *gal3* siRNAs transfected moDCs; black population, isotype control. Numbers in inset indicate geometrical mean fluorescence intensity.(C) NT, *gal9,* and/or *gal3* siRNA-transfected cells were challenged with zymosan for 60 min, after which cells were fixed, stained, and the phagocytic index calculated. Graphs show representative results for one donor. Each dot represents phagocytic index obtained for one image field; 20--30 image fields were analyzed per condition, and each image field contained 10--20 cells.(D) Representative images from results shown in (C).(E) Quantification and statistical analysis of experiments depicted in (D). Results show the mean ± SEM for four independent donors. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA- and between NT and *gal3* siRNA-transfected cells.\*p \< 0.05, \*\*p \< 0.005, \*\*\*p \< 0.0001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Galectin-9 Is Essential for Phagocytosis by Dendritic Cells {#sec2.2}
-----------------------------------------------------------

We previously identified Galectin-9 as part of the DC-SIGN-mediated, a phagocytic receptor present in immature DCs, phagosomes, although no functional studies were performed to assess the role of Galectin-9 in DC function ([@bib8], [@bib42], [@bib41], [@bib11], [@bib23]). Co-immunoprecipitation experiments revealed DC-SIGN association with Galectin-9 in DCs, demonstrating their molecular interaction ([Figure 2](#fig2){ref-type="fig"}A). To examine whether this interaction occurs in the cytosolic compartment and/or at the extracellular matrix, co-immunoprecipitations were performed on lactose-treated moDCs and in the presence of lactose to prevent unspecific binding of Galectin-9 to DC-SIGN during cell lysis. Lactose impairs cell surface glycan-based interactions mediated by Galectins by competing for their major ligands, which dissociates Galectins from the cell surface ([@bib36], [@bib10]). As shown, addition of lactose successfully removed Galectin-9 from the surface of moDCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Nonetheless, Galectin-9 was found to still bind DC-SIGN, albeit to a lesser extent than in the untreated control ([Figure 2](#fig2){ref-type="fig"}B). These data indicate that Galectin-9 binds to DC-SIGN both extra- and intracellularly. To investigate the role of Galectin-9 in DC-SIGN-mediated phagocytosis, Gal-9 KD and NT control (referred to as wild-type \[WT\]) DCs were challenged with zymosan particles. Galectin-9 protein knockdown (90%) was confirmed by flow cytometry ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and western blotting ([Figure S2](#mmc1){ref-type="supplementary-material"}C). No significant differences in zymosan binding were observed between NT and *gal9* siRNA-transfected DCs ([Figure S2](#mmc1){ref-type="supplementary-material"}D), implying that Galectin-9 is not required for particle binding. To study the involvement of Galectin-9 in particle uptake, the phagocytic index was calculated for each of the conditions and specified time points ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S2](#mmc1){ref-type="supplementary-material"}E). Gal-9 KD resulted in impaired zymosan internalization 60 min after challenging moDCs ([Figure 2](#fig2){ref-type="fig"}D). Quantification of the number of particles internalized per cell revealed that the impaired uptake upon Gal-9 KD is likely due to a decrease in the number of zymosan particles internalized per cell rather than a decrease in the total amount of cells able to uptake particles ([Figure 2](#fig2){ref-type="fig"}E). Gal-9 KD did not alter DC-SIGN membrane expression or receptor internalization excluding that the uptake defect was due to deficient receptor surface levels ([Figure S3](#mmc1){ref-type="supplementary-material"}). Next, WT and Gal-9 KD moDCs were incubated with a DC-SIGN-blocking antibody (clone AZN-D1) or isotype control before challenging them with zymosan particles. AZN-D1 does not induce DC-SIGN signaling and has a modified Fc region that cannot be recognized by the Fc receptors expressed on DCs ([@bib23], [@bib57]). As expected, blocking DC-SIGN resulted in defective zymosan uptake by NT-transfected moDCs, although zymosan uptake was unaffected by the addition of isotype controls ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Analysis performed on multiple donors confirmed our observations, and zymosan uptake was significantly impaired upon DC-SIGN blocking, indicating that DC-SIGN is the major receptor for zymosan in DCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These results demonstrate that Galectin-9 is an essential component in DC-SIGN receptor-mediated uptake by DCs.Figure 2Galectin-9 Is Required for Optimal Phagocytic Capacity in DCs(A) moDCs were lysed and whole-cell extract prepared for incubation with anti-DC-SIGN antibody (H200) or isotype control (total rabbit IgG). Immunoprecipitated (IP) complexes were resolved and probed with DC-SIGN- and Galectin-9-specific antibodies. Graph shows quantification of Galectin-9 content of each sample using ImageJ.(B) moDCs were treated with 35 mM lactose for 48 h before being lysed as per (A). IP complexes were resolved and probed with DC-SIGN- and Galectin-9 specific antibodies. Graph shows quantification of Galectin-9 content of each sample using ImageJ.(C) NT or *gal9* siRNA-transfected cells were challenged with zymosan for the indicated time points. After this time, cells were fixed, stained, and phagocytic indexes calculated for each time point. Graphs show representative results for one donor. Each dot represents phagocytic index obtained for each microscopic field, each of which contained 10--20 cells.(D) Quantification and statistical analysis of experiments shown in (C). Twenty frames were analyzed for each donor and transfection. Results show the mean value ± SEM for four independent donors. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA-transfected cells for all time points.(E) NT or *gal9* siRNA-transfected cells were challenged as per (C) and the number of internalized zymosan particles quantified for each frame. Ten to twenty frames were analyzed for each condition. Data represent mean percentage of DCs that had internalized the specified number of particles of one representative donor out of three independent experiments. For statistical analysis two-way ANOVA followed by a Bonferroni post hoc test was applied.n.s.: p \> 0.05; \*p \< 0.05, \*\*p \< 0.005. See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

Zymosan uptake experiments were also performed with murine bone marrow-derived dendritic cells (BMDCs) from WT and galectin-9-deficient (*galectin9* ^−/−^) mice. In line with human DCs, lack of Galectin-9 in murine DCs resulted in defective phagocytic capacity, suggesting an evolutionarily conserved role for Galectin-9 in phagocytosis ([Figures 3](#fig3){ref-type="fig"}A and 3B). To investigate the effect of Galectin-9 in DC-mediated immunity against fungal pathogens, galectin-9-null mice were immunized with heat-inactivated *Candida albicans* and DC function analyzed ([Figure 3](#fig3){ref-type="fig"}C). Although we were not able to quantify phagocytosis *in vivo*, murine DCs lacking Galectin-9 displayed a significant decrease in cytokine secretion upon infection, indicating poor initiation of a proper immune response ([Figures 3](#fig3){ref-type="fig"}D--3G).Figure 3Galectin-9 Function in DC Is Conserved between Mouse and Human and Alters Dendritic Cell-Mediated Immune Responses *In Vivo*(A) Bone marrow-derived dendritic cells (BMDCs) obtained from either wild-type (control) or galectin-9-null (galectin-9 ^−/−^) mice were seeded on coverslips, challenged with zymosan for 60 min, and the phagocytic index calculated. Results show the mean phagocytic index value ± SEM for three independent mice. Unpaired Student\'s t test was conducted between wild-type and galectin-9 ^−/−^ mice. \*p \< 0.05.(B) Representative images from results shown in (A). Scale bar, 10 μm.(C--G) (C) Scheme depicting work protocol to assess anti-fungal immunity in galectin-9-null animals. Four wild-type (WT) and galectin-9 ^−/−^ mice were injected with heat-inactivated *Candida albicans*. Three hours after injection, lymph nodes and spleen were removed, single-cell suspensions made, and cells seeded onto 96-well plates. Spleen cell suspensions were re-stimulated with *C. albicans,* and 24 h after seeding cytokine secretion was measured in supernatants by ELISA. Tumor necrosis factor (TNF)-α production in spleen (D) or lymph node (E) samples. Interleukin (IL)-12 production in spleen (F) or lymph node (G) samples. Graph shows the mean value ± SEM for four animals. Unpaired Student\'s t test was conducted between WT and Gal9 KO cells. \*p \< 0.05.

Intracellular Galectin-9 Controls Plasma Membrane Structure in Dendritic Cells {#sec2.3}
------------------------------------------------------------------------------

To examine whether the extra- or the intracellular pool of Galectin-9 was responsible for the defect in phagocytosis, moDCs were treated with lactose to remove extracellular galectins from the cell surface before being challenged with zymosan particles. Although lactose treatment effectively reduced the surface levels of Galectin-9 and Galectin-3 ([Figures 4](#fig4){ref-type="fig"}A and 4B), no effects on zymosan uptake were observed compared with untreated cells ([Figure 4](#fig4){ref-type="fig"}C). Lactose was also added during zymosan incubation, and no differences in the phagocytic index of moDCs treated with lactose were observed, regardless of whether lactose was present during zymosan incubation ([Figure S5](#mmc1){ref-type="supplementary-material"}). This indicates that the intracellular pool of Galectin-9 is responsible for particle uptake by moDCs and that particle binding and internalization are independent of Galectin-9-mediated interactions at the cell surface. These findings led us to hypothesize that Galectin-9 may interact with specific cytoskeleton components, which could alter the stability and/or the formation of phagosomes. To address this, Gal-9 KD and WT DCs were analyzed for their uptake ability upon treatment with cytochalasin D (cytD), which blocks actin polymerization by its binding to actin filaments. Addition of cytD resulted in a significant decrease of particle uptake in WT cells in contrast to Gal-9 KD moDCs that were not affected by cytD after challenging cells for 60 min ([Figure 5](#fig5){ref-type="fig"}A). Earlier time points were also analyzed, but DCs were still unable to take up any particles due to the inhibition of the actin cytoskeleton polymerization ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). We excluded that this was due to a difference in particle binding between WT and Gal-9 KD cells (L. Querol Cano, unpublished data) or cell viability, which was not affected upon treatment with cytD ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Similar results were obtained when DCs were treated with increasing concentrations of cytD, confirming *gal9* siRNA-transfected cells to be less sensitive to actin disruption than their WT counterparts ([Figure S6](#mmc1){ref-type="supplementary-material"}D). To corroborate an impairment in the actin cytoskeleton upon Galectin-9 depletion, levels of F-actin were measured in WT and Gal-9 KD cells moDCs. A decrease of approximately 20% in the total levels of F-actin was seen in moDCs depleted for Galectin-9, confirming a specific effect for this lectin in the actin cytoskeleton arrangement ([Figures 5](#fig5){ref-type="fig"}B and 5C). Experiments performed with *galectin-9* ^−/−^ murine BMDCs confirmed this defect in cellular actin content ([Figures 5](#fig5){ref-type="fig"}D and 5E). Furthermore, confocal imaging showed that the percentage of F-actin-positive phagosomes was reduced upon Gal-9 KD in moDCs challenged with zymosan particles by approximately 40% ([Figures 5](#fig5){ref-type="fig"}F and 5G) in line with our previous observation ([Figure 5](#fig5){ref-type="fig"}B). These data suggest that depletion of Galectin-9 leads to reduced actin filament formation both under basal conditions and around phagosomes. To further verify Galectin-9 involvement in directly controlling the actin cytoskeleton, super-resolution laser scanning microscopy was performed on ventral plasma membrane sheets of moDCs. These studies demonstrated that Galectin-9 closely associates with the cortical actin cytoskeleton under basal conditions ([Figure 6](#fig6){ref-type="fig"}).Figure 4Intracellular Galectin-9 Is Responsible for Modulating Dendritic Cell Function(A and B) moDCs were treated with 35 mM lactose for 48 h, and removal of extracellular (A) but not intracellular (B) Galectin-9 and Galectin-3 expression was confirmed by flow cytometry. Red population, untreated cells; blue population, lactose-treated cells; black population, isotype control. Numbers in inset indicate gMFI. Panels depict representative results for one donor, and graphs show the mean phagocytic index ± SEM for three independent donors. Unpaired Student\'s t test was conducted between untreated control and lactose-treated cells.(C) Control or lactose-treated cells were challenged with zymosan for 60 min. Cells were then fixed, stained, and the phagocytic index calculated. Graphs show the mean ± SEM for three independent donors. Unpaired Student\'s t test was conducted between untreated control and lactose-treated cells. n.s.: p \> 0.05, \*p \< 0.05. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.Figure 5Galectin-9 Modulates Cellular Actin Cytoskeleton(A) NT or *gal9* siRNA-transfected moDCs were pretreated with 1.25 μg/mL cytochalasin D (cytD) for 10 min before being challenged with zymosan for 60 min. Cells were then fixed, stained, and the phagocytic index calculated. Twenty frames were analyzed for each condition and donor. Data represent mean average phagocytic index ± SEM for one representative donor out of three independent experiments. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA-transfected cells.(B) Actin levels were analyzed by flow cytometry in NT and *gal9* siRNA-transfected moDCs. Results are expressed as percent gMFI of *gal9* siRNA-transfected cells relative to their NT control. Data represent mean average % gMFI for three independent experiments ± SEM. One-way t test was conducted.(C) Representative histogram for actin expression after Galectin-9 knockdown. Gray area, NT siRNA-transfected moDCs; red area, *gal9* siRNA-transfected moDCs; black dotted line, isotype control. Numbers in inset indicate gMFI.(D) Actin levels of BMDC obtained from wild-type (control) or galectin-9 ^−/−^ mice were analyzed by flow cytometry. Data represent mean average gMFI for three independent mice ± SEM.(E) Representative histogram for actin expression. Gray line, control BMDCs; red line, galectin-9 ^−/−^ BMDCs. Numbers in inset indicate gMFI.(F) Representative confocal images of F-actin rings in moDCs transfected as in (A) and challenged with zymosan particles for 15 min.(G) Quantification of the percentage of F-actin-positive phagosomes of experiments shown in (F).Data represent mean average ± SEM. n.s.: p \> 0.05, \*p \< 0.05, \*\*p \< 0.005, \*\*\*p \< 0.001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.Figure 6Galectin-9 Closely Associates with the Actin CytoskeletonVentral plasma membrane sheets from day 5 moDCs were stained for actin and Galectin-9 and imaged with super-resolution microscopy. A representative plasma membrane sheet out of four independent experiments is shown. Gamma correction (0.2) was applied to enhance the contrast of the actin image. Lower images: magnification of the area indicated in the upper images. Scale bar, 10 μm. Arrows indicate sites of Galectin-9 and actin colocalization.

To unravel the mechanism underlying Galectin-9 function in plasma membrane integrity and structure, we exploited atomic force microscopy (AFM) to analyze the cellular stiffness of moDCs transfected with either NT or *gal9* siRNA. Nanomechanical probing of the cells was achieved by obtaining a series of force-distance curves on selected points of the cell surface. A sharp non-functionalized cantilever with a radius of approximately 35 nm was brought into contact with a flat area of a single DC attached to a glass coverslip applying a mechanical force ([Figure 7](#fig7){ref-type="fig"}A). The use of a combined bright-field AFM setup allowed for accurately positioning the cantilever over specific areas of interest on the cell surface ([Figure 7](#fig7){ref-type="fig"}B). Analysis of the approach force-distance curves obtained for each point of interest allowed calculation of the cytoskeletal stiffness using the linearized Sneddon equation ([Figure 7](#fig7){ref-type="fig"}C). For this purpose, minimum and maximum fit boundaries (shown in blue) were defined respectively as 10% and 70% of the maximum force after baseline correction ([Figure 7](#fig7){ref-type="fig"}C). The portion of the curves that was used for fitting with the linearized model is shown in purple, and the separation distance that corresponds to this fit region is in the range of 200--600 nm ([Figure 7](#fig7){ref-type="fig"}C). Given that the thickness of the lipid bilayer is approximately 4 nm ([@bib63]), it is plausible to presume that the underlying cytoskeletal structures such as cortical actin and peripheral cytoplasm were also probed in our experiments. The mechanical characterization performed on DCs shows that moDCs lacking Galectin-9 have a decreased cytoskeletal rigidity compared with their WT counterparts ([Figure 7](#fig7){ref-type="fig"}D), in line with the defect in their cytoskeleton previously observed.Figure 7Galectin-9 Alters Cytoskeletal Membrane Rigidity(A) Schematic AFM single-cell elasticity measurement setup showing an overview of the AFM cantilever in contact with the DC and the cantilever movement used to measure the change in cantilever deflection.(B) Optical image of *gal9* siRNA-transfected moDCs obtained during the mechanical probing of the cell. White dot shows the position of the tip, and the red cross depicts the region of interest at the membrane that was indented with the cantilever.(C) Representative force-distance curves obtained on *gal9* siRNA-transfected (black) and NT siRNA (red) moDCs and curve-fitting approach to determine the Young\'s modulus of elasticity. Blue lines correspond to upper- and lower-fit boundaries (70% and 10% of the maximum force, respectively); purple lines show fitted portion of the curves used to calculate Young\'s modulus.(D) Young\'s modulus of elasticity was calculated by fitting the force-distance curves indicated in (C). Data represent mean average Young\'s modulus of elasticity ± SEM of three independent donors, and each data point shows the average value for three different locations for each moDC. Ten to thirty cells were analyzed for each donor in each independent experiment. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA-transfected cells. \*\*\*p \< 0.001.

As it is well known that actin polymerization is mediated by small GTPases of the Rho family including Rac1 ([@bib13], [@bib43], [@bib56], [@bib45]), we investigated the effect of Galectin-9 depletion on Rac1 activation by specifically measuring its GTP-bound fraction using a G-LISA colorimetric assay. Incubation of control moDCs with zymosan particles resulted in a fast induction of Rac1-GTP activity already after 5-min stimulation ([Figures 8](#fig8){ref-type="fig"}A and 8B), which was sustained in time ([Figures 8](#fig8){ref-type="fig"}A and 8C). Depletion of Galectin-9 abrogated Rac1 induction, and no increase in its GTP-bound form could be observed upon zymosan stimulation in moDCs transfected with *gal9* siRNA at any of the time points analyzed ([Figures 8](#fig8){ref-type="fig"}A--8C). The recruitment of total Rac1 to nascent phagocytic cups was also impaired upon Gal-9 KD ([Figures 8](#fig8){ref-type="fig"}D--8F), suggesting that Galectin-9 promotes both Rac1 recruitment and activity on phagosomes.Figure 8Galectin-9 Promotes Phagosomal Rac1 Activity(A) NT and *gal9* siRNA-transfected moDCs were challenged with zymosan particles for the indicated time points. After this time, cells were lysed, total protein was quantified, and Rac1-GTP activation was determined. Results are expressed as fold increase Rac1-GTP levels and relative to the unstimulated corresponding sample. Data represent mean average Rac1-GTP fold induction ± SEM of three independent donors. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA-transfected cells.(B and C) Each symbol represents one independent donor, and lines connect paired NT and *gal9* siRNA-transfected moDCs after stimulation with zymosan for either 5 min (B) or 30 min (C).(D) NT or *gal9* siRNA-transfected moDCs were challenged with zymosan_FITC for 5 min before being stained for F-actin (magenta) and Rac1 (blue) and imaged with super-resolution microscopy. A representative confocal image out of 9 images is shown. Scale bar, 10 μm. Arrows indicate overlap between Rac1 and F-actin signal on phagocytic cups.(E) Magnification of representative phagocytic cups in NT and *gal9* siRNA-transfected moDCs treated as in (D).(F) Number of Rac1- and/or F-actin-positive phagocytic cups found on moDCs treated as in (D). Nine images containing between 20 and 30 cells were analyzed for each condition. Data represent mean average number of phagocytic cups ± SEM. Unpaired Student\'s t test was conducted between NT and *gal9* siRNA-transfected cells.\*p \< 0.05; \*\*p \< 0.01; n.s p \> 0.05.

Taken together, intracellular Galectin-9 controls plasma membrane structure via modulating Rac1 activity and actin polymerization, which underlies Galectin-9 requirement for phagocytosis in DCs.

Discussion {#sec3}
==========

Galectins have gained increasing interest for their role as extracellular organizers of plasma membrane components via glycan-mediated interactions. Nonetheless, their mechanism of action remains poorly understood, and in particular, their intracellular functions are ill-defined ([@bib8]). Here, we identified a previously unrecognized function for intracellular Galectin-9 in actin cytoskeleton reorganization and report a novel, functional interaction between Galectin-9 and the C-type lectin receptor DC-SIGN at the cytosol of DCs. Several members of the Galectin family are expressed in the cytosol, and some, such as Galectin-1 or Galectin-3 are predominantly intracellular proteins ([@bib39], [@bib60], [@bib14], [@bib31]). Very little is known regarding the localization and function of cytoplasmic Galectin-9, although it has been implicated in protein folding and signal transduction ([@bib33], [@bib59]). Our study now demonstrates that the large intracellular pool of Galectin-9 is responsible for the phagocytic capacity in DCs by modulating plasma membrane structure, revealing a novel function for Galectins in cytoskeleton remodeling. This was observed in both human and murine cells, which indicates Galectin-9 as an evolutionarily conserved lectin required for maintaining the cortical cytoskeleton structure and function in DCs. Our data support a model in which Galectin-9 is essential for DC-SIGN-mediated phagocytosis, by (1) maintaining plasma membrane and cortical actin stiffness and (2) controlling receptor function ([Figure 9](#fig9){ref-type="fig"}). We identified that the underlying mechanism involves Galectin-9-dependent activation and recruitment of Rac1-GTP upon particle incubation, which triggers actin polymerization and the subsequent formation of phagocytic cups.Figure 9Model of the Role of Galectin-9 in Membrane Rigidity and Particle Uptake(A) Intracellular Galectin-9 controls polymerization of cortical actin through interacting with C-type lectin phagocytic receptors and modulating Rac1 activity, which is essential for plasma membrane integrity and successful target uptake.(B) In the absence of Galectin-9, Rac1 activity is impaired, which results in abrogation of phagocytosis through decreased cortical actin levels and the subsequent loss of membrane rigidity.

In line with this, our AFM studies demonstrate that Galectin-9-depleted cells have a less rigid plasma membrane and cortical cytoskeleton, rendering them unable to adequately modify their structure upon particle engulfment. Moreover, inhibition of actin polymerization did not affect the phagocytic ability of Gal-9 KD cells in contrast to WT cells. Although actin executes a pivotal function in phagocytosis, little is known regarding the mechanisms that govern F-actin recruitment to a nascent phagosome due to the lack of high-resolution data ([@bib5]). Our data support a new concept in which intracellular Galectin-9 is required for actin polymerization, directly controlling plasma membrane rigidity, by enhancing the activity of the actin-binding protein Rac1. In line with this, Galectin-1 has been recently shown to re-activate F-actin protein levels ([@bib47]). Similarly, intracellular Galectin-3 has been proved to enhance phagocytosis in macrophages by its interaction with F-actin in the phagocytic cups ([@bib49], [@bib51]). Intracellular ligands have been proposed to bind Galectins through protein-protein interactions independent of carbohydrate-mediated recognition, although whether both proteins interact directly or through an intermediary molecule is not known ([@bib19], [@bib32], [@bib52]). Whether Galectin-9 function in our study is carbohydrate independent remains to be elucidated, but knockdown of Galectin-9 in the presence of other Galectins was sufficient to induce defects in actin polymerization and cellular rigidity in DCs. DC-SIGN is known to interact with actin and Lsp-1, an F-actin-interacting protein through its cytoplasmic tail ([@bib53]), which likely allows for extracellular particle binding, plasma membrane deformation, and actin polymerization to occur simultaneously. Moreover, DC-SIGN signaling results in enhanced RhoA-GTPase activity ([@bib20], [@bib28]). Our data now support that depletion of intracellular Galectin-9 is sufficient to disrupt the cytosolic complex of DC-SIGN with actin-binding proteins, ultimately impairing cytoskeleton reorganization and causing a reduction in the cellular phagocytic capacity. We identified Galectin-9 as an integral component of the actin cytoskeleton as well as of the intracellular DC-SIGN-associated complex, and it is conceivable that Galectin-9 exerts its effects on the cytoskeleton remodeling by directly linking F-actin filaments, actin remodeling proteins, and DC-SIGN in a multi-protein complex ([Figure 9](#fig9){ref-type="fig"}). Alternatively, Galectin-9 may connect DC-SIGN with other plasma membrane receptors known to associate with actin, such as CD44, which has been previously shown to interact with Galectin-9, as a component of DC-SIGN-directed phagosomes in DCs ([@bib61], [@bib8]).

Aside of its direct effects on DC-SIGN, we expect Galectin-9 depletion to have additional effects on the function of other lectin receptors involved in phagocytosis (mannose receptor, complement receptor 3, TLR2) ([@bib55], [@bib62]). To date, extracellular Galectin-9 has been previously shown to interact with CD44, glucose transporter-2, immunoglobulin E, and Tim-3, a T cell type 1 membrane protein, known to be involved in T cell apoptosis and phagocytosis of apoptotic cells ([@bib61], [@bib64]). All these interactions, though, are carbohydrate dependent and mediated via glycan-lectin associations. To the best of our knowledge, no intracellular binding partners have been previously reported for Galectin-9.

The intracellular functions of Galectin-9 and particularly its role in phagocytosis have not been previously addressed, and our work is in line with Galectin-3 and Galectin-1 function in particle uptake, highlighting the broad importance of intracellular Galectins in enhancing cellular uptake ([@bib22], [@bib49], [@bib6], [@bib9], [@bib38], [@bib46]). Furthermore, our studies with primary DCs demonstrate that disruption of glycan interactions solely alters particle uptake but not their binding to the cell membrane, which is in agreement with previous findings ([@bib49]).

In summary, our work demonstrates a novel role for intracellular Galectin-9 in the regulation of the phagocytic activity through reorganization of the actin cytoskeleton that underlies plasma membrane rigidity in DCs. Given the plethora of cellular biological processes Galectin-9 is involved in, this novel intracellular Galectin-9 mechanism of action contributes to the general understanding of plasma membrane structure and their implications in cell function.

Limitations of the Study {#sec3.1}
------------------------

In this study we identified Galectin-9 as novel regulator of the actin cytoskeleton and plasma membrane structure in DCs. We have also defined and characterized the interaction and functional relationship between Galectin-9 and the phagocytic receptor DC-SIGN. Further work could be performed to confirm that both proteins interact intracellularly. Given the cytosolic localization and function of Galectin-9, a further in-depth characterization of the role Galectin-9 in governing the intracellular signaling pathway downstream of DC-SIGN would also be pertinent.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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========================

Document S1. Transparent Methods and Figures S1--S6

We thank Sjoerd van Helvert and Roel Hammink for help with atomic force microscopy and Erik Jansen for help in preparing the yeast cells for the *in vivo* immunizations. This work is supported by the Dutch Cancer Society (Grant 11618, to L.Q.C.); A.B.v.S. is supported by the Netherlands Organisation for Scientific Research (NWO-ALW VIDI Grant 864.11.006), the Dutch Cancer Society (KUN2014-6845), and the European Research Council (ERC CoG 724281). C.G.F. is recipient of the Netherlands Organization for Scientific Research Spinoza Prize and ERC Adv Grant ARTimmune (834618).

Author Contributions {#sec5}
====================

Conceptualization: L.Q.C. C.G.F., and A.B.v.S; Methodology and Investigation: L.Q.C., O.T., Y.D., S.D., A.v.D., S.I.B., B.J., and K.v.d.D. Resources: T.N. and M.H. Writing -- Original draft: L.Q.C., A.C., C.G.F., and A.B.v.S. All authors read and provided input on the manuscript. Writing -- Review and Editing: L.Q.C. and A.B.v.S. Funding Acquisition: L.Q.C., S.B., C.G.F., and A.B.v.S.

Declaration of Interests {#sec6}
========================

The authors would like to declare the following competing interests: Drs. Niki and Hirashima are board members of GalPharma Co., Ltd. This does not alter the authors\' adherence to all iScience policies on sharing data and materials.

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2019.11.019>.

[^1]: These authors contributed equally

[^2]: These authors contributed equally

[^3]: Lead Contact
